Position in NUVL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$6,146
+$917 QoQ
Shares Held
60
+15.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NUVL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Bare Financial Services, Inc holds $191,078 across 74 Biotechnology names. NUVL ranks #8 (3.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
218 | $13,668 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
179 | $12,193 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
47 | $12,139 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
53 | $10,580 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
95 | $10,011 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
226 | $7,507 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
831 | $7,485 | |
| 8 | NUVL |
Nuvalent, Inc.
This page
|
60 | $6,146 |
All Filings in NUVL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,146 | 60 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $5,229 | 52 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $1,383 | 16 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $610 | 8 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||